|
Jul 1
|
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
|
|
Jun 25
|
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
|
|
Jun 11
|
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
|
|
Feb 11
|
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
|
|
Nov 15
|
Femasys Third Quarter 2024 Earnings: Misses Expectations
|
|
Nov 12
|
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
|
|
Nov 12
|
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
|
|
Nov 7
|
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
|
|
Nov 1
|
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
|
|
Oct 30
|
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
|
|
Oct 2
|
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
|
|
Sep 18
|
Femasys Announces Infertility Clinic Customers from Coast to Coast
|
|
Aug 30
|
Femasys secures CE mark certification for FemVue MINI solution
|
|
Aug 29
|
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
|
|
Aug 27
|
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
|
|
Jun 21
|
Femasys gains CE Mark approval for women’s health products
|
|
Jun 20
|
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
|
|
May 7
|
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
|
|
May 2
|
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
|
|
Mar 28
|
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
|